Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF in difficult to treat spontaneous bacterial peritonitis
NCT02468089Completed
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- May 2015
- Primary completion
- Aug 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of sargramostim in spontaneous bacterial peritonitis (SBP), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Total number of patients cured from Spontaneous Bacterial Peritonitis at 1 week. Started May 2015; status: completed.
02
Drugs
sargramostim
03
Conditions
spontaneous bacterial peritonitis (SBP)
Beyond the preview
Go deeper on NCT02468089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02468089.